IRIS PubliCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.181
EU - Europa 1.964
AS - Asia 417
AF - Africa 25
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 4.611
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.152
IT - Italia 679
SE - Svezia 495
IE - Irlanda 238
CN - Cina 143
DE - Germania 109
SG - Singapore 109
FR - Francia 102
RU - Federazione Russa 72
IN - India 45
GB - Regno Unito 44
FI - Finlandia 43
IR - Iran 23
CZ - Repubblica Ceca 21
UA - Ucraina 21
ES - Italia 20
TR - Turchia 20
BE - Belgio 17
CH - Svizzera 17
CA - Canada 14
CI - Costa d'Avorio 14
RO - Romania 14
HK - Hong Kong 13
JP - Giappone 12
MK - Macedonia 12
NL - Olanda 12
PA - Panama 11
PH - Filippine 11
RS - Serbia 11
IL - Israele 10
KR - Corea 10
PL - Polonia 10
EG - Egitto 9
BR - Brasile 7
PT - Portogallo 6
AR - Argentina 5
AT - Austria 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
MX - Messico 3
PE - Perù 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
AU - Australia 2
BT - Bhutan 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
MY - Malesia 2
ZA - Sudafrica 2
AL - Albania 1
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
GL - Groenlandia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.611
Salva come PNG Salva come JPEG
Città #
Chandler 588
Ashburn 314
Dublin 209
New York 162
Rome 144
Milan 104
Marseille 64
Singapore 60
Princeton 58
San Mateo 56
Boston 53
Moscow 46
Wilmington 33
Bremen 28
Helsinki 28
Los Angeles 28
Chicago 26
Palermo 26
Nanjing 24
Ann Arbor 22
Dearborn 21
Beijing 20
Boardman 18
Brno 18
Fairfield 18
Pune 18
Houston 15
Kish 15
Abidjan 14
Redmond 14
Andover 12
Brussels 12
Redwood City 12
Washington 12
Menlo Park 11
Seattle 11
Turin 11
Cattolica 10
Munich 10
Salamanca 10
Skopje 10
Augusta 9
Bologna 9
Busto Arsizio 9
Florence 9
Lancaster 9
Seoul 9
Toronto 9
Bari 8
Lappeenranta 8
London 8
Norwalk 8
Woodbridge 8
Cairo 7
Hebei 7
Jacksonville 7
Jinan 7
Shanghai 7
Hong Kong 6
Leawood 6
Niš 6
Shenzhen 6
Amsterdam 5
Changsha 5
Harrisburg 5
Jiaxing 5
Lisbon 5
Mountain View 5
Naaldwijk 5
Nanchang 5
Paris 5
San Diego 5
Secaucus 5
Shenyang 5
Stockholm 5
São Paulo 5
Tokyo 5
Wandsworth 5
Ancona 4
Barcelona 4
Bern 4
Bitonto 4
Brindisi 4
Cambridge 4
Fort Worth 4
Genoa 4
Giugliano in Campania 4
Guangzhou 4
Krakow 4
Kunming 4
Lawrence 4
Monza 4
Naples 4
Palagiano 4
Reggio Calabria 4
San Francisco 4
Tappahannock 4
Trento 4
Trieste 4
Ankara 3
Totale 2.694
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 209
Performance of Upper Limb module for Duchenne muscular dystrophy 107
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 106
Revised upper limb module for spinal muscular atrophy: Development of a new module 95
Developmental milestones in type I spinal muscular atrophy 77
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 75
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 75
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 74
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 74
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 73
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 71
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 71
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 70
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 69
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 67
Developmental milestones in type I spinal muscular atrophy 66
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 65
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 64
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 63
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 62
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 62
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 61
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 60
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 59
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 57
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 57
Longitudinal natural history in young boys with Duchenne muscular dystrophy 57
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 57
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 55
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 54
Assessing floppy infants: a new module 54
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 53
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 53
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 53
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 52
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 50
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 50
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 50
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 48
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 48
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 48
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 48
Clinical Variability in Spinal Muscular Atrophy Type III. 47
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 47
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 47
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 46
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 46
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 46
Development of an academic disease registry for spinal muscular atrophy 45
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 44
Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. 43
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 43
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. 43
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 43
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 41
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 40
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 39
Gain and loss of abilities in type II SMA: A 12-month natural history study 39
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 39
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 38
Revised upper limb module for spinal muscular atrophy: 12 month changes 38
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 38
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 38
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 37
First international workshop on rehabilitation management and clinical outcome measures for spinal muscular atrophy 37
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 36
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 36
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 35
Risdiplam in Type 1 Spinal Muscular Atrophy 35
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 35
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 34
Longitudinal natural history of type I spinal muscular atrophy: A critical review 34
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 34
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 33
Revised upper limb module for spinal muscular atrophy: Development of a new module 33
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 33
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 32
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 31
Sleep disorders in spinal muscular atrophy 30
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 30
An observational study of functional abilities in infants, children, and adults with type 1 SMA 29
Development of an International SMA Bulbar Assessment for Inter-professional Administration 26
An observational study of functional abilities in infants, children, and adults with type 1 SMA 25
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 24
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 23
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 21
Language Development in Preschool Duchenne Muscular Dystrophy Boys 20
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 18
Long term follow-up of scoliosis progression in type II SMA patients 18
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
An observational study of functional abilities in infants, children, and adults with type 1 SMA 17
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 17
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 16
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 16
Language Development in Preschool Duchenne Muscular Dystrophy Boys 15
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 15
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study 15
Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach 13
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 12
Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy 11
Totale 4.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.392
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.392
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020137 33 0 1 3 3 20 16 2 5 8 44 2
2020/202164 1 7 3 3 11 2 4 1 9 7 15 1
2021/2022693 45 7 15 92 52 27 17 95 50 41 122 130
2022/20232.008 179 244 122 269 135 256 143 177 273 37 101 72
2023/20241.655 60 295 70 139 76 293 195 83 42 85 130 187
2024/202552 52 0 0 0 0 0 0 0 0 0 0 0
Totale 4.746